DCVC

The U.S. military’s newly established counter-UAS task force has made its first acquisition, selecting Fortem Technologies’ DroneHunter® as it begins standing up a more centralized approach to counter-drone procurement. As Janes reports, the move signals an early emphasis on fielded, operational capabilities as the task force starts shaping how C-UAS systems will be evaluated, acquired, and scaled across the military. Read the Janes coverage: https://lnkd.in/g2JCjFnT

Congratulations to the Winners of the WEF UPLINK Water Resilience Challenge. These 10 Companies were selected by a team of water industry experts from hundreds of applicants as Top Innovators. Those who choose to pursue improving the condition of water and wastewater around the world, to me, are a special breed. They are practical and gritty, and driven by purpose, mission and a call to serve. They are deserving of our respect and appreciation. Well done to each of the Top Innovators and to the hundreds of companies who pursued this WEF Uplink Challenge. https://lnkd.in/eZkTJT5K

As capital markets tighten, the industry is increasingly receptive to a belief DCVC has championed for over a decade: revolutionary technology often demands a long-term view. Simply put, we are in a hurry to do things that take time. DCVC Co-Founder and Managing Partner Zachary Bogue will join the World Economic Forum's panel "Investors and the Patience Premium" to address a critical question for the broader market: How ready is the investment community to take a more patient approach to investing in the potential of a revolutionary technology?

Compact, ruggedized, real-world-ready #quantum navigation from Q-CTRL that ensures mission completion even in GPS-denied environments Yet another DCVC-backed #quantum technology company showing the critical commercial and national security impact that is their hallmark.

Why is water the catalyst for the next wave of global growth? 💧 Hear from DCVC Managing Partner Zachary Bogue and other leaders from the public and private sectors on the World Economic Forum's panel on closing the water infrastructure gap. Details below 👇

This year’s JPM was pretty quiet overall, but DCVC’s TechBio companies were not—with each showing massive progress: NOETIK announced that GSK had signed a $50M partnership agreement to use Noetik’s cancer foundation models to accelerate the development of drugs for non-small cell lung cancer and colorectal cancer. This deal is momentous: as far as we know, it’s the world’s first example of a pure-play AI licensing model in TechBio. And NOETIK is just getting started. Proxima—which already had billions of $ in signed contracts across Johnson & Johnson, Bristol Myers Squibb, and Blueprint Medicines (now part of Sanofi)—announced an $80M seed round led by DCVC and joined by NVIDIA. The company’s proprietary AI-driven tech drives the rational discovery and design of new molecular glues and other proximity-based, small-molecule medicines. Recursion’s recently appointed CEO Najat Khan, PhD (formerly Chief R&D and Commercial Officer) took the stage to make clear that Recursion (Nasdaq: RXRX) is moving from insights to proof points, “innovating with intention, and matching bold ambition with real discipline.” She cited progress in its FAP program as an important demonstration of AI-identified biology translating into a meaningful clinical outcome. Recursion has deals across pharma worth potentially tens of billions of $. Relation announced a deal with Deerfield Management to create jointly owned companies to pursue novel drug targets. This follows on Relation’s deal last month with Novartis (to study targets for atopic diseases) worth $55M up front and up to $1.7B in milestones, and additionally royalties, along with $26M in funding co-led by DCVC, NVIDIA, and Magnetic Ventures. And in late 2024, Relation struck an agreement with GSK (toward new drugs for fibrotic disease and osteoarthritis) worth $45M up front and potentially hundreds of millions each across multiple targets. We’ve been investing in TechBio for two decades, because we see tremendous opportunity in marrying deep compute, exquisite proprietary data, and hard-earned biological insight. Who wins? Patients everywhere. Congrats to everyone on these outstanding teams! #JPMHealthcare #JPM2026

Thrilled to join the SPIE Vision Tech gathering at #PhotonicsWest on the Perspectives from Venture Capital panel with Richard Oberreiter and Sam Spencer-Pittman, moderated by Steve Weinstein If you’re building at the intersection of compute, sensing, and autonomy, this is where you want to be. See you in San Francisco! 🔗https://spie.org/Vision26 DCVC

🚀 2025 was a defining year for Reality Defender. We saw rapid adoption across industries, new levels of market urgency, and were recognized by Gartner® as the Company to Beat in deepfake detection. These shifts signal what we've long believed: defending against synthetic media is no longer optional, it's foundational to enterprise security and trust. We're starting 2026 by releasing our most advanced visual detection model to date. It's purpose-built to stop high-stakes synthetic threats targeting identity verification and real-time communications. And we’re not slowing down. In the months ahead, we’ll be launching new capabilities and strategic partnerships that further raise the bar for AI threat detection. #AITrust #DeepfakeDetection #Cybersecurity #EnterpriseSecurity #RealityDefender